Related Experiment Video
Updated: Jan 11, 2026
Merkel Cell Polyomavirus Infection and Detection
Published on: February 7, 2019
Molecular Characterization of Polyomavirus-Positive and Negative Merkel Cell Carcinoma
Poorva Vaidya1, Sharon Wu2, Dave Bryant2
1Division of Hematology/Oncology, UC Irvine School of Medicine, Orange, CA 92868, USA.
Background/Objectives:
Immune checkpoint inhibitors (ICIs) are frontline treatment for advanced Merkel Cell Carcinoma (MCC), regardless of viral status. Frontline ICIs provide durable benefit to only half of patients, highlighting a need for alternative therapies. In this study, the objective is to leverage whole exome sequencing (WES) and transcriptome sequencing (WTS) to distinguish genomic alterations associated with ICI response. Investigate differential genomic alterations between virus-positive (VP) and virus-negative (VN)-MCC to identify novel therapeutic targets.
Methods:
A total of 95 MCC cases underwent WES and WTS. Utilizing computational pipelines applied to WES, we identified viral status and tumor mutational burden (TMB). RNA-seq data was used to characterize the immune microenvironment.
Results:
Of 95 MCC cases, 57 (60%) were VP-MCC and 38 (40%) were VN-MCC. Median TMB was higher in VN-MCC (27.5 vs. 1 Muts/Mb). Mutations in TP53, RB1, NOTCH1, KMTD2, KMT2C, and PIK3CA were primarily found in VN-MCC. MAPK Pathway Activity Score, NK cell infiltration, and the immune checkpoint gene CD276 in VN-MCC tumors were upregulated. No overall survival (OS) difference was identified between VP and VN-MCC, even after ICIs.
Conclusions:
MCC oncogenesis and treatment response transcend viral status. While mutational analysis confirms previous findings, assessment of the transcriptome and tumor microenvironment suggests alternate therapeutic targets.
Insights
Genomic analysis of Merkel Cell Carcinoma (MCC) reveals distinct alterations in virus-negative tumors, suggesting new therapeutic targets beyond viral status for immune checkpoint inhibitors (ICIs).
Area of Science:
- Oncology
- Genomics
- Immunology
Background:
- Immune checkpoint inhibitors (ICIs) are standard frontline therapy for advanced Merkel Cell Carcinoma (MCC).
- However, only half of patients achieve durable benefit, necessitating alternative treatment strategies.
- Understanding the genomic landscape associated with treatment response is crucial.
Purpose of the Study:
- To differentiate genomic alterations linked to ICI response in MCC.
- To investigate distinct genomic profiles between virus-positive (VP) and virus-negative (VN)-MCC.
- To identify novel therapeutic targets by analyzing WES and WTS data.
Main Methods:
- Whole exome sequencing (WES) and transcriptome sequencing (WTS) were performed on 95 MCC cases.
- Computational pipelines identified viral status and tumor mutational burden (TMB).
- RNA-seq data characterized the tumor immune microenvironment.
Main Results:
- 57% of MCC cases were VP-MCC and 40% were VN-MCC.
- Virus-negative MCC exhibited higher TMB and distinct mutations (e.g., TP53, RB1, PIK3CA).
- Upregulated MAPK pathway activity, NK cell infiltration, and CD276 were observed in VN-MCC.
Conclusions:
- Merkel Cell Carcinoma (MCC) development and treatment response are not solely dictated by viral status.
- Transcriptome and tumor microenvironment analyses reveal potential alternative therapeutic targets.
- Genomic insights can guide personalized treatment strategies for MCC patients.
